Literature DB >> 26977437

The effect of statins therapy in aortic stenosis: Meta-analysis comparison data of RCTs and observationals.

Ying Zhao1, Rachel Nicoll2, Yi Hua He1, Michael Y Henein2.   

Abstract

Aortic stenosis has been shown to share the same risk factors as atherosclerosis which suggested a potential benefit from statins therapy. Fourteen studies which provided the effect of statins treatment on aortic stenosis (AS) were meta-analyzed, including 5 randomized controlled trials (RCTs) and 9 observational studies. In the RCTs, statins did not have any influence on peak aortic valve velocity, peak valve gradient, mean valve gradient, aortic valve area and aortic calcification compared to controls. In the observational studies, the peak valve velocity, peak gradient and aortic valve area showed less progression in the statins group compared to controls. This article describes data related article title "The effect of statins on valve function and calcification in aortic stenosis: a meta-analysis" (Zhao et al., 2016) [1].

Entities:  

Year:  2016        PMID: 26977437      PMCID: PMC4781966          DOI: 10.1016/j.dib.2016.02.045

Source DB:  PubMed          Journal:  Data Brief        ISSN: 2352-3409


Specifications table Value of the data These data segregate the results of the randomized controlled trials (RCT) and the observational studies that assessed the use of statins in patients with aortic stenosis. The data show clearly that the RCTs refuted any potential benefit of statins in aortic stenosis in contrast to the observational studies which showed potential slow progression, although not consist. This clear discrimination should assist and guide future trials to better accurate ways for assessing the effect of statins in aortic stenosis. Researchers might also be allowed in including our data analysis as part of future trials or meta-analyses.

Data

The data presented here showed the statins group (as a whole) had less increase in annual peak valve velocity (p=0.003), annual peak gradient (p=0.006)). All these were only observed in observational studies (p=0.002, p<0.001) but not in RCTs (p=0.48, p=0.49). The annual mean gradient showed no any significant changes between statin and control groups (p=0.05), and it was the case in observational subgroup (p=0.08) and in RCTs subgroup (p=0.40) (Fig. 1). While, the statins group had a trend of less changes in aortic valve area (p=0.05) and less changes in aortic calcification (p=0.03) in observational subgroup but not in RCTs subgroup (p=0.75 and p=0,91) and in total (p=0.09 and p=0.22) (Fig. 2).
Fig. 1

The statins group had less increase in annual peak valve velocity (p=0.003) and peak gradient (p=0.006) in total, and this was only in observational studies but not in RCTs. The annual mean gradient did not show any significant change in total (p=0.05), observationals and RCTs subgroups.

Fig. 2

There was no difference between statins and non-statins treatment regarding the annual changes of aortic valve area (p=0.09),also it was the case between observational and RCTs subgroups. The annual increase of aortic valve calcification did not show any significant changes between statins and control groups (p=0.22) and in RCTs subgroups, but it was not the case in observational subgroups.

Experimental design, materials and methods

Design, materials and methods

We searched a medical database (PubMed) using the MeSH keywords (“aortic valve stenosis” and “Hydroxymethylglutaryl-CoA Reductase Inhibitors”) together and in combination, having limited the search to studies reported only in English prior to April 2015 and those which used adults ≥19 years of age. Fourteen studies were identified including 5 RCTs [2], [3], [4], [5], [6] and 9 observational studies [7], [8], [9], [10], [11], [12], [13], [14], [15]. The mean follow-up period of the studies ranged between 12 months and 5.6 years. Data from patients commenced on statins were compared with controls and between subgroups.

Statistical analysis

The data was extracted from each study and analyzed using the Revman software 5.3. The annual changes in peak aortic velocity, peak and mean valve gradient, aortic valve area and aortic calcification were compared between the statins group and the control group as well as the subgroups. A p<0.05 was defined as statistical significance.
Subject areaClinical research, Meta-analysis
More specific subject areaMedicine
Type of dataFigure
How data was acquiredMeta-analysis
Data formatAnalyzed
Experimental factorsAortic stenosis parameters
Experimental features14 eligible studies selected from Pubmed
Data source locationCanada, Austria, Norway, Portugal, Spain, USA, UK, Italy, Germany, Iran
Data accessibilityData is with this article
  15 in total

Review 1.  The effect of statins on valve function and calcification in aortic stenosis: A meta-analysis.

Authors:  Ying Zhao; Rachel Nicoll; Yi Hua He; Michael Y Henein
Journal:  Atherosclerosis       Date:  2016-01-19       Impact factor: 5.162

2.  Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis.

Authors:  Luis M Moura; Sandra F Ramos; José L Zamorano; Isabel M Barros; Luis F Azevedo; Francisco Rocha-Gonçalves; Nalini M Rajamannan
Journal:  J Am Coll Cardiol       Date:  2007-01-22       Impact factor: 24.094

3.  Effect of hydroxymethylglutaryl coenzyme a reductase inhibitors on the progression of calcific aortic stenosis.

Authors:  G M Novaro; I Y Tiong; G L Pearce; M S Lauer; D L Sprecher; B P Griffin
Journal:  Circulation       Date:  2001-10-30       Impact factor: 29.690

4.  HMG CoA reductase inhibitor (statin) and aortic valve calcium.

Authors:  David M Shavelle; Junichuro Takasu; Matthew J Budoff; SongShou Mao; Xue Qiao Zhao; Kevin D O'Brien
Journal:  Lancet       Date:  2002-03-30       Impact factor: 79.321

Review 5.  Statins but not angiotensin-converting enzyme inhibitors delay progression of aortic stenosis.

Authors:  Raphael Rosenhek; Florian Rader; Nicole Loho; Harald Gabriel; Maria Heger; Ursula Klaar; Michael Schemper; Thomas Binder; Gerald Maurer; Helmut Baumgartner
Journal:  Circulation       Date:  2004-08-30       Impact factor: 29.690

6.  Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis.

Authors:  Anne B Rossebø; Terje R Pedersen; Kurt Boman; Philippe Brudi; John B Chambers; Kenneth Egstrup; Eva Gerdts; Christa Gohlke-Bärwolf; Ingar Holme; Y Antero Kesäniemi; William Malbecq; Christoph A Nienaber; Simon Ray; Terje Skjaerpe; Kristian Wachtell; Ronnie Willenheimer
Journal:  N Engl J Med       Date:  2008-09-02       Impact factor: 91.245

7.  Effect of statin treatment on aortic valve and coronary artery calcification.

Authors:  Emile R Mohler; Hao Wang; Elizabeth Medenilla; Craig Scott
Journal:  J Heart Valve Dis       Date:  2007-07

8.  Effect of Lipid lowering with rosuvastatin on progression of aortic stenosis: results of the aortic stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER) trial.

Authors:  Kwan Leung Chan; Koon Teo; Jean G Dumesnil; Andy Ni; James Tam
Journal:  Circulation       Date:  2010-01-04       Impact factor: 29.690

9.  Atorvastatin therapy is not associated with slowing the progression of aortic stenosis: findings of a randomized controlled trial.

Authors:  Yunes Panahi; Amirhossein Sahebkar; Hamid Reza Taghipour; Yahya Dadjou; Bahram Pishgoo; Amir Sobh Rakhshankhah
Journal:  Clin Lab       Date:  2013       Impact factor: 1.138

10.  Prognosis and risk factors in patients with asymptomatic aortic stenosis and their modulation by atorvastatin (20 mg).

Authors:  Wolfgang Dichtl; Hannes Franz Alber; Gudrun Maria Feuchtner; Florian Hintringer; Markus Reinthaler; Thomas Bartel; Alois Süssenbacher; Wilhelm Grander; Hanno Ulmer; Otmar Pachinger; Silvana Müller
Journal:  Am J Cardiol       Date:  2008-07-02       Impact factor: 2.778

View more
  1 in total

1.  Statin treatment and healthy adherer effects.

Authors:  T An; J Hao; S Sun; R Li; M Yang; G Cheng; M Zou
Journal:  Osteoporos Int       Date:  2017-05-29       Impact factor: 4.507

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.